Your Trusted Brand for Over 35 Years

Muscular Dystrophy References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Tidball JG, Wehling-Henricks M. Evolving therapeutic strategies for Duchenne muscular dystrophy: Targeting downstream events. Pediatr Res. 2004 Dec;56(6):831–41.
  2. Guglieri M, Magri F, et al. Molecular etiopathogenesis of limb girdle muscular and congenital muscular dystrophies: Boundaries and contiguities. ClinChimActa. 2005 Nov;361(1-2):54–79.
  3. Nieto-Ceron S, del Campo LF, et al. Muscular dystrophy by merosin deficiency decreases acetylcholinesterase activity in thymus of Lama2dy mice. J Neurochem. 2005 Nov;95(4):1035–46.
  4. Leighton S. Nutrition for boys with Duchenne muscular dystrophy. (Review). Nutrition & Dietetics: J Dieticians Asso of Australia. 2003 March;60(1):11–6.
  5. Louis M, Lebacq J, et al. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve. 2003 May;27(5):604–10.
  6. Felber S, Skladal D, et al. Oral creatine supplementation in Duchenne muscular dystrophy: A clinical and 31P magnetic resonance spectroscopy study. Neurol Res. 2000 Mar;22(2):145–50.
  7. Anderson JL, Head SI, et al. Brain function in Duchenne muscular dystrophy.Brain. 2002;125:4–13.
  8. Billard C, Gillet P, et al. Reading ability and processing in Duchenne muscular dystrophy and spinal muscular atrophy. Dev Med Child Neural. 1998;40:12–20.
  9. Dubowitz V. Muscle disorders in childhood. 2nd ed. London: WB Saunders Company Ltd; 1995.
  10. Griggs RC, Pandya S, et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology. 1989 Feb;39(2 Pt 1):219–22.
  11. Balagopal P, Olney R, et al. Oxandrolone enhances skeletal muscle myosin synthesis and alters global gene expression profile in Duchenne muscular dystrophy. Am J PhysiolEndocrinolMetab. 2006 Mar;290(3):E530–E539.
  12. Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: Review of efficacy and safety. Drugs. 2004;64(7):725–50.
  13. Balaban B, Matthews DJ. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: Long-term effect. Am J Phys Med Rehabil. 2005 Nov;84(11):843–50.
  14. Manzur AY, Kuntzer T, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2004;(2):CD003725.
  15. Beenakker EA, Fock JM, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: A randomized controlled trial. Arch Neurol. 2005 Jan;62(1):128–32.
  16. Yilmaz O, Karaduman A, et al. Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Eur J Neurol. 2004 Aug;11(8):541–4.
  17. Passaquin AC, Renard M, et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. NeuromusculDisord. 2002 Feb;12(2):174–82.
  18. PerskyAM,Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev. 2001 Jun;53(2):161–76.
  19. Tarnopolsky MA, Mahoney DJ, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology. 2004 May 25;62(10):1771–7.
  20. Walter MC, Reilich P, et al. Creatine monohydrate in myotonic dystrophy: A double-blind, placebo-controlled clinical study. J Neurol. 2002 Dec;249(12):1717–22.
  21. Walter MC, Lochmuller H, et al. Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study. Neurology. 2000 May 9;54(9):1848–50.
  22. Payne ET, Yasuda N. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve. 2006 Jan;33(1):66–77.
  23. Morley N, Clifford T, et al. The green tea polyphenol (-)-epigallocatechingallate and green tea can protect human cellular DNA from ultraviolet and visible radiation-induced damage. PhotodermatolPhotoimmunolPhotomed. 2005 Feb;21(1):15–22.
  24. Katiyar SK, Elmets CA. Green tea polyphenolic antioxidants and skin photoprotection (Review). Int J Oncol. 2001 Jun;18(6):1307–13.
  25. Katiyar SK. Skin photoprotection by green tea: Antioxidant and immunomodulatory effects. Curr Drug Targets Immune EndocrMetabolDisord. 2003 Sep;3(3):234–42.
  26. Zaveri NT. Green tea and its polyphenoliccatechins: Medicinal uses in cancer and noncancer applications. Life Sci. 2006 Mar 27;78(18):2073–80.
  27. Cooper R, Morre DJ, et al. Medicinal benefits of green tea: Part I. Review of noncancer health benefits. J Altern Complement Med. 2005 Jun;11(3):521–8.
  28. Dorchies OM, Wagner S, et al. Green tea extract and its major polyphenol (-)-epigallocatechingallate improve muscle function in a mouse model for Duchenne muscular dystrophy. Am J Physiol Cell Physiol. 2006 Feb;290(2):C616–C625.
  29. Buetler TM, Renard M, et al. Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. Am J ClinNutr. 2002 Apr;75(4):749–53.
  30. Folkers K, Simonsen R. Two successful double blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenie atrophies. BiochimBiophysActa. 1995;1271:281–6.
  31. Siciliano G, Mancuso M, et al. Coenzyme Q10, exercise lactate and CTG trinucleotide expansion in myotonic dystrophy. Brain Res Bull. 2001 Oct-Nov 1;56(3-4):405–10.
  32. Tedeschi D, Lombardi V, et al. Potential involvement of ubiquinone in myotonic dystrophy pathophysiology: New diagnostic approaches for new rationale therapeutics. Neurol Sci. 2000;21(5 Suppl):S979–S980.
  33. Aparicio LF, Jurkovic M, et al. Decreased bone density in ambulatory patients with duchenne muscular dystrophy. J PediatrOrthop. 2002;22:179–81.
  34. Larson CM, Henderson RC.Bone mineral density and fractures in boys with Duchenne muscular dystrophy.JPediatrOrthop. 2000;20:711–4.
  35. Bianchi ML, Mazzanti A, et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int. 2003 Sep;14(9):761–7.
  36. Webb AR, Kline L, et al. Influence of season and latitude on the cutaneous synthesis of vitamin D3: Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J ClinEndocrinolMetab. 1988 Aug;67(2):373–8.
  37. Levis S, Gomez A, et al. Vitamin D deficiency and seasonal variation in an adult South Florida population. J ClinEndocrinolMetab. 2005 Mar;90(3):1557–62.
  38. Hankard R, Mauras N, et al. Is glutamine a ‘conditionally essential’ amino acid in Duchenne muscular dystrophy? ClinNutr. 1999 Dec;18(6):365–9.
  39. Hankard RG, Hammond D, et al. Oral glutamine slows down whole body protein breakdown in Duchenne muscular dystrophy. Pediatr Res. 1998 Feb;43(2):222–6.
  40. Escolar DM, Buyse G, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol. 2005 Jul;58(1):151–5.
  41. Chaubourt E, Fossier P, et al. Nitric oxide and 1-arginine cause an accumulation of utrophin at the sarcolemma: A possible compensation for dystrophin loss in Duchenne muscular dystrophy. Neurobiol Dis. 1999 Dec;6(6):499–507.
  42. Kasai T, Abeyama K, et al. Decreased total nitric oxide production in patients with duchenne muscular dystrophy. J Biomed Sci. 2004 Jul-Aug;11(4):534–7.
  43. Chaubourt E, Voisin V, et al. Muscular nitric oxide synthase (muNOS) and utrophin. J Physiol Paris. 2002 Jan-Mar;96(1-2):43–52.
  44. Barton ER, Morris L, et al. Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve. 2005 Dec;32(6):751–60.
  45. Marques MJ, Luz MA, et al. Muscle regeneration in dystrophic mdx mice is enhanced by isosorbidedinitrate. NeurosciLett. 2005 Jul 15;382(3):342–5.
  46. Archer JD, Vargas CC, et al. Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J. 2006 Apr;20(6):738–40.
  47. Conte Camerino D, Tricarico D, et al. Taurine and skeletal muscle disorders. Neurochem Res. 2004 Jan;29(1):135–42.
  48. Ruegg UT, Nicolas-Metral V, et al. Pharmacological control of cellular calcium handling in dystrophic skeletal muscle.NeuromusculDisord. 2002 Oct;12Suppl 1:S155–S161.
  49. Pierno S, De Luca A, et al. Chronic administration of taurine to aged rats improves the electrical and contractile properties of skeletal muscle fibers. J PharmacolExpTher. 1998 Sep;286(3):1183–90.
  50. De Luca A, Pierno S, et al. Alteration of excitation-contraction coupling mechanism in extensor digitorumlongus muscle fibres of dystrophic mdx mouse and potential efficacy of taurine. Br J Pharmacol. 2001 Mar;132(5):1047–54.
  51. De Luca A, Pierno S, et al. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J PharmacolExpTher. 2003 Jan;304(1):453–63.
  52. Tidball JG, Wehling-Henricks M. Damage and inflammation in muscular dystrophy: Potential implications and relationships with autoimmune myositis. CurrOpinRheumatol. 2005 Nov;17(6):707–13.
  53. Porter JD, Khanna S, et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet. 2002 Feb 1;11(3):263–72.
  54. Ferrucci L, Cherubini A, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J ClinEndocrinolMetab. 2006 Feb;91(2):439–46.
  55. La Guardia M, Giammanco S, et al. Omega 3 fatty acids: Biological activity and effects on human health. Panminerva Med. 2005 Dec;47(4):245–57.
  56. Zamaria N. Alteration of polyunsaturated fatty acid status and metabolism in health and disease.ReprodNutr Dev. 2004 May-Jun;44(3):273–82.